<DOC>
	<DOCNO>NCT02143726</DOCNO>
	<brief_summary>This randomized phase II trial study effect , good bad , use everolimus along sorafenib tosylate versus sorafenib tosylate alone treat patient advanced radioactive iodine refractory thyroid cancer . Sorafenib tosylate everolimus may stop growth tumor cell block enzymes need cell growth . The addition everolimus sorafenib tosylate may cause shrinkage thyroid cancer may prevent grow could also cause side effect sorafenib tosylate alone . It yet know whether treatment sorafenib tosylate everolimus well , , bad sorafenib tosylate alone .</brief_summary>
	<brief_title>Sorafenib Tosylate With Without Everolimus Treating Patients With Advanced , Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer</brief_title>
	<detailed_description>This randomized Phase II trial compare progression-free survival ( PFS ) sorafenib everolimus versus sorafenib alone patient radioactive iodine refractory hurthle cell thyroid cancer . Prior study show median PFS generally around 4.5 month sorafenib alone disease population . It hop combination everolimus sorafenib increase median PFS least 9 month . In addition PFS , trial also compare confirm response rate , overall survival ( OS ) adverse event rate sorafenib everolimus vs. sorafenib alone . The primary secondary objective study list . Primary Objective : To compare progression free survival sorafenib everolimus versus sorafenib alone patient radioactive iodine refractory Hurthle cell thyroid cancer Secondary Objective : To compare confirm response rate , overall survival adverse event rate sorafenib everolimus versus sorafenib alone . Treatment continue disease progression unacceptable adverse event . Patients follow 5 year randomization .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Eligibility Criteria : 1 . Central pathology review submission Patients must 10 representative hematoxylin eosin ( H &amp; E ) stain thyroid tissue slide OR tumor block available submission central pathology review . This review mandatory prior registration confirm eligibility . 2 . Measurable disease Patients must measurable disease Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion , define least one lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral compute tomography ( CT ) scan . CT must perform within 28 day registration . 3 . Radioactive iodine ( RAI ) refractory disease define 1 following : Patients receive great 600 mCi radioactive iodine lifetime OR RAIavid metastatic lesion remain stable size progress despite RAI treatment within 9 month RAI treatment OR 10 % increase serum thyroglobulin ( thyroidstimulating hormone [ TSH ] suppression ) within 9 month RAI treatment OR Index metastatic lesion nonRAI avid diagnostic RAI scan OR Presence fluorodeoxyglucose ( FDG ) avid metastatic lesion positron emission tomography ( PET ) /CT scan ( standardized uptake value [ SUV ] max &gt; 5 single lesion ) 4 . Progressive disease define RECIST criterion ≤ 14 month 5 . Patients must metastatic disease locally advance unresectable disease 6 . Prior treatment Patients may receive prior radiation therapy index lesion ≥ 28 day prior registration protocol document progression RECIST criterion . Prior radiation therapy nonindex lesion allow ≥ 28 day prior registration protocol . Prior RAI therapy allow ≥ 90 day prior registration protocol evidence progression ( define ) document interim ( diagnostic study use &lt; 10 mCi RAI consider RAI therapy ) . Prior chemotherapy allow ≥ 28 day prior registration protocol . Patient may receive number prior line therapy . No prior use sorafenib mammalian target rapamycin ( mTOR ) ( include phosphoinositide 3kinase [ PI3k ] protein kinase B [ AKT ] ) inhibitor treatment thyroid cancer . 7 . No history major surgery ≤ 28 day registration 8 . No history intracranial brain metastasis 9 . Cardiovascular disease . No history follow ≤ 6 month registration : Myocardial infarction unstable angina New York Heart Association grade III great congestive heart failure Cerebrovascular accident Grade 3 4 peripheral ischemia Grade 3 4 thromboembolic event 10 . Liver disease : No history follow : Child Pugh Class B C liver disease `` Chronic active '' hepatitis define : 1 . Hepatitis B surface antigen ( HBsAg ) &gt; 6 month 2 . Serum hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) 20,000 IU/ml ( 105 copies/ml ) , low value 2,00020,000 IU/ml ( 104105 copies/ml ) often see hepatitis B e antigen ( HBeAg ) negative chronic hepatitis B 3 . Persistent intermittent elevation alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) level 4 . Liver biopsy show chronic hepatitis moderate severe necroinﬂammation 11 . No history gastrointestinal fistula gastrointestinal perforation &lt; 90 day registration . 12 . No known history prolong QT syndrome 13 . No Grade 3 4 hypertension ( systolic blood pressure [ BP ] &gt; 160 diastolic BP &gt; 100 ) control medication prior registration . 14 . Concomitant medication : Chronic concomitant treatment strong inhibitor cytochrome P450 3A4 ( CYP3A4 ) allow study . Patients strong CYP3A4 inhibitor must discontinue drug 14 day prior registration study . Chronic concomitant treatment strong CYP3A4 inducer allow . Patients must discontinue drug 14 day prior start study treatment . Patients require anticoagulation must stable dose medication prior registration . 15 . Not pregnant nursing , study involve investigational agent whose genotoxic , mutagenic teratogenic effect develop fetus newborn unknown . Therefore , woman childbearing potential , negative serum pregnancy test do ≤ 7 day prior registration require . 16 . Age ≥ 18 year 17 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 18 . Required Initial Laboratory Values : Absolute neutrophil count ( ANC ) ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 mg/dL OR Calculated creatinine clearance ≥ 30 mL/min Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) ( AST ) ≤ 2.5 x ULN Fasting serum cholesterol ≤ 300 mg/dL 19 . Documentation disease : Histologic Documentation Eligible patient must histopathologically confirm Hürthle cell thyroid cancer central review .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>